Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03331289 · ClinicalTrials.gov registry record · Phase 4
Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
A Phase 4 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 4
- Development phase
- 107
- Enrollment target
NCT03331289 is a Phase 4 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 107 participants.
The verdict
NCT03331289, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 107 participants
- Enrollment target
Study Summary
Research Design/Plan: After screening, each subject will receive 1 measurements of Endogenous Glucose Production \[EGP\] with prime-continuous Infusion of 3-3H-glucose. After completing the EGP measurement each subject will receive a Double Tracer Oral Glucose Tolerance Test \[OGTT\]. Methods: Visit 1: Screening. Medical history will be obtained, physical exam performed, and pregnancy test performed. Visit 2: Endogenous Glucose Production Measurement: The rate of EGP will be measured with 3-3H-glucose. Visit 3: Double Tracer OGTT
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
- DRUG Exenatide
- DRUG Exenatide and Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2018-02-28 |
| Est. Completion | 2022-11-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03331289
The ClinicalTrials.gov registry entry for NCT03331289 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03331289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03331289 about?
NCT03331289 is a clinical study titled "Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria". Research Design/Plan: After screening, each subject will receive 1 measurements of Endogenous Glucose Production \[EGP\] with prime-continuous Infusion of 3-3H-glucose. After completing the EGP measurement each subject will receive a Double Tracer Oral Glucose Tolerance Test \[OGTT\]. Methods: Visi...
What is the current status of trial NCT03331289?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 107 participants. The study started on 2018-02-28. Estimated completion is 2022-11-04.
What interventions are being tested in trial NCT03331289?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG), Exenatide (DRUG), Exenatide and Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT03331289?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.